Other groups with large disconnects between sellside and investor expectations include Beigene, Alnylam and Acceleron.
The SITC breaks its own embargo, and the ensuing chaos sees Replimune, Iovance and Incyte move.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.
The company is one of very few to have studied combining PD-1 and PD-L1 blockade, an approach still in need of scientific validation.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.